Category Archives: Glucose Monitoring

Senseonics Q4 ’25 Earnings; BI Terminates Ph2 MASH Program

Two cardiometabolic-related news items have been observed: Senseonics hosted its Q4 ’25 earnings call (view press release), and BI discontinued its Ph2 BI 770371 asset in MASH (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

FDA Approves Biocon’s Generic Saxenda; Novo Partners for Oral Peptide Development; Medtronic Launches MiniMed Go in EU; Bloom Doses First Patient in Ph1 Obesity Trial; BreezeBio Raises $60M in Series B; Verdiva Completes Ph2b Obesity Enrollment; MHRA Raids Illegal Manufacturing Facilities in UK

A series of cardiometabolic-related news items has been observed from Biocon, Novo Nordisk, Medtronic, Bloom Science, Verdiva Bio, and MHRA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Lilly Launches Zepbound KwikPen; Allurion Gains FDA Approval; Eversense 365 Launches with twiist AID System; February CHMP Agenda

A series of cardiometabolic-related news items has been observed from Lilly, Allurion Therapeutics, Sequel Med Tech/Senseonics, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Tandem Q4 ’25 Earnings; Verdiva Obesity Pipeline

Two cardiometabolic-related news items have been observed: Tandem Diabetes Care hosted its Q4 ’25 earnings call (press release; slides) and Verdiva Bio shared updates to its obesity pipeline (view article). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Beta Bionics and Insulet Q4 ’25 Earnings; Lilly Taltz+Zepbound PsO Combination Data; Zealand Ph1a Kv1.3 Inhibitor Topline Results

A series of cardiometabolic-related news items has been observed from Beta Bionics, Insulet, Lilly, and Zealand Pharma. Below, FENIX provides highlights and insights on the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Dexcom, Vertex, and Biocon Q4 ’25 Earnings; Lilly Stockpiles Orforglipron Ahead of Launch

A series of cardiometabolic-related news items has been observed by Dexcom, Lilly, Vertex, and Biocon. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

AZ’s Oral GLP-1RA Progresses to Ph3; Kailera and Hengrui Ph2 Oral Ribupatide Data; Pfizer Registers VESPER-5; Ph3 Zenagamtide vs Semaglutide H2H Study; Sava Preliminary CGM Data

A series of cardiometabolic-related news items has been observed from AstraZeneca, Kailera Therapeutics/Hengrui Pharma, Pfizer, Novo Nordisk, and Sava Technologies. Below, FENIX provides highlights and insights on the respective news items.

This content is for members only.

Already a member? Log in here

Hims Launches Compounded Sema Pill; Novo London, AbbVie, GSK, and Novartis Q4 ’25 Earnings; Stelo Smart Meal Logging Updates; Abbott FDA Warning Letter and Class I Recall; Rare Pediatric PRV Program Reauthorized; Sciwind Ph3 OSA Study

A series of cardiometabolic-related news items has been observed from Hims & Hers, Novo Nordisk, AbbVie, GSK, Novartis, Dexcom, Abbott, the White House, and Sciwind Biosciences. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Reports Topline Cagrisema T2DM Data; Additional Nimacimab Results; Medtronic Expands 780G Access; SanegeneBio Partners with Roche; NMPA Approves Sciwind’s Ecnoglutide in T2DM

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Skye Bioscience, Medtronic, SanegeneBio/Roche, and Sciwind Biosciences. Below, FENIX provides highlights and insights for the respective news items, including a hypothesis around Novo’s cagrisema strategy.

This content is for Read Less members only.

Already a member? Log in here

Roche and Sanofi Q4 ’25 earnings; New Fractyl Revita Data

Three cardiometabolic-related news items have been observed: Roche (view press release; view slides) and Sanofi (view press release; view slides; view infographic) hosted their respective Q4 ’25 earnings calls; and Fractyl Health announced 6-month results from its REMAIN-1 Midpoint Cohort for the Revita procedure (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here